Member Info for roger65

Thought those late trades were at 3.10p

Gilham’s was at a price of 3.10p so perhaps those three late trades at 3.05p are not Director buys after all

I guess they would have all been announced in the same RNS actually (unless they used a different broker, I dare say Gilham has his own). Not sure.

M doesn’t matter anyway. It’s good news which ever way one looks at it.

Ah yes Bladey. Hadn’t clocked that. On that basis looks highly likely there are two more Director Buy RNSs on their way. What were the amounts of those other late trades all at 3.1p? Think they were around the £20k mark? That’ll be Gino and Russ

Normally in this scenario the Director buying would notify the others before going ahead so as to give them the opportunity to buy too at the same share price level, rather than send the sp north and make his colleagues have to pay a higher price. Therefore don’t think there will be further Director buys. It’s still a very good sign though that no raise due any time soon and certainly not at a lower price and that more sales are expected - which is already in the public domain so does not constitute inside information. Gilham is a wily old fox though and May we’ll have been given a mid to long term heads up from a primatial buyer and is getting in asap

Gilham or anyone for that matter would not just throw £30k at a stock for nothing.

It does imply there’s nothing brewing that constitutes ‘market sensitive information’ in their current knowledge. Think it can only suggest genuine confidence that further sales will be achieved before too long and that longer term things for GDR look better.

Let’s hope so Jimi. Not doing the share price any harm at all which is a relief and pleasant change.

Wow, just wow.

Gilham now owns approx 1.7m shares?

Even i own 4.6m and I’m sure there are many lths pis who hold more that! And annoyingly that puts paid to my theory the company is about to be bought out. Bugger. Going to take much much longer to recover losses then. Patience and much more coffee needed

Seems to me that, on achieving this ‘key milestone’ of gaining NICE approval, the company has done as little as possible in terms of shouting about it from the roof tops. Indeed no PR at all, not a single interview either in print or video, and cursory X posts that are somewhat short on content. The efforts to suppress the share price by mms in spite of more than two weeks now of sometimes double the amount of buys to sells suggests all the GDR players are in on something. I think this will be bought out fairly cheaply and then be taken private, with PH, Wallbrook, Addleshaw etc all taking their cut of profits or being handed a stake in the future entity that becomes GDR.

No other explanation. Actually, there is one, and that’s that GDR simply have no sales lined up other than the recently announced package for hospitals in Greater Manchester & they know they have nothing to say and thus will just stay silent until the next placing is needed. They’ve got enough cash even with an increased monthly cash burn going into 2025 of £600k per month - £600k per month for a company now earning about £250k in sales per year - to last until early next year before PH start to take it down to much lower levels. In March 2025 the highest share price in the previous 12 months will be something like 6.5p and they can do another placing at 1.5p rinsing pis, and then sell the company for about 6.5p per share.

Sounds bad and would be pretty awful for lths but…that would present one more opportunity for pis to throw the kitchen sink in at 1.5p again and take away a very decent profit if sold at 6p per share. That would be a mcap of about £35m which I think many would now be sorely tempted to accept given the precarious position GDR is in regarding sales. The business world sees GDR as ‘troubled’ and it’s not hard to see why going on the current paucity of comms coming from the company, supposedly celebrating such a key milestone. Just my rambling thoughts as I enjoy a morning coffee or two.

Peel Hunt. They are also the nomad.

Pis won’t get anything from any of the GDR representatives, Peel Hunt, Addleshaw or Wallbrook. Don’t for one second imagine this is a level playing field you’re betting you’re money on.

Nomad is a joke. No point. They’ll most likely be in on any potential deal to take the company private so you’ll get bugger all out of them. They’ll be doing all they can to keep everything under wraps so aiding pis is just about the last thing they would ever consider!!

‘Stroke unit boost for troubled Genedrive’

This focuses more on immediate departure of former CEO and share price decline over the last year from 33p to 1.47p.

Hardly something for Gino to ignore. Get a sharp and upbeat interview out there ffs! Saying there’s been a key milestone achieved is like a ‘stay off the grass’ sign to investors ie still a long way to go.

Eureka, why on Earth would you add another person to a sales team that has only managed on average one sales contract each over the last two years. Sack both of them and find just one new person who knows how to sell !

* values the tech at

Personally think GdR is lucky to have a current mcap of nearly £17m. Commercially it is all over the place (figuratively, not literally more’s the pity) and currently has sales worth approx £250k per annum so doesn’t even cover one month of its costs so the mcap is what the market Vapor’s the tech at, rightly speaking. I’m hoping MT RNR1 will be taken up by more NHS Trusts very soon or abroad but if not then this is going to drift lower. Not what any of us wants, Slacker apart, but think we’ve got to recalculate the time it’s going to take to create the income. Hope there’s a buy out offer first though that’s now looking less likely

Utter blx….as per usual. Knew it was a mistake to empty the bin.

So many green boxes today! Hardly any posts worthwhile reading. Waste of 10 mins scrolling through.

No one knows what’s going to happen and it certainly looks at the moment as if Gino is going to be no better than Butt or Cheek at generating a PR story around GDR and providing regular comms. Switch off and come back in Sept.

About bloody time!

Don’t let Emerald’s rubbish irritate you. He’s obviously in and needs to make his £250. As soon as he has he’ll be out and hopefully some other bb will cop his inane and relentless posts.

This will be great in time but unfortunately it’s going to take far longer than any of us lths would have wished for.

A big step forwards would be one of the central London hospitals adopting one of GDR’s tests. None have to date and clearly this was cause for frustration for James Cheek so my gut feeling is they’ve been approached and know about the tests but have said no or not yet… hopefully CYP2C19 once approved for use for cardiac arrest patients will have to be adopted a little quicker than I’d just being used as a back up for lab testing for stroke victims.

Nothing anyone can do but be patient. I am hoping GDR can at least garner enough support to avoid being taken private.

I disagree about the US clinical testing partner not being the same as the partner for distribution with whom GDR were supposedly dotting the i’s and crossing t’s back in December 2023. Either they are one and the same or that particular agreement has gone pear shaped because it doesn’t take 8 months to announce an agreement that is in the final stages of being signed and sealed. I am more than half expecting this same partner to be the one that buys GDR out and that it is indeed Beckman Coulter. Gino will be kept on as the CEo of that division and be allowed to focus on the science whilst the new owner hangs over all the commercial aspects to their vastly experienced, globally established and highly successful sales department.

Just need time and enough support until the offer lands.

His responsibilities now are not focused on the science but providing value to the mcap and share holders. He should learn from Budd and Cheek’s mistakes in staying silent for ages and dribbling sales info on to the market. He should be doing interviews to fully the market of every conversation he is hearing and emphasise the near term and long term potential. AIM is based on sentiment and GDR has very little atm so silence will only see the mcap drop further. We need a PR story and lots of visibility an comms imo to get everyone talking about which sales deals might land next….

I think yr numbers are out padrock

Test is £80. 2000 patients are Year. £160k but more like £100k clear profit. One can assume an assessment will be made after 6 months but if that number of £91m saving per year is banded about then there will be more sales before long.

Sorry, stock but you are clearly on a mission to run this down at what ever cost and no matter what news lands. I’m surprised you’re shorting GDR now but each to their own. Anyway it’s relentlessly negative so you’re binned, for a while at least, perhaps until there is another RNS and then I’ll see if you’re still intent on every possible negative spin on things. Bye

Stocksaint you are being disingenuous.

‘ Obviously the AIHL "rollout" is not progressing’

You know perfectly well the NICE recommendation was Conditional and that the MT RNR1 test is up for full commission either towards the end of this year or early next so there will be no full roll out until then. You know this of course.